These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 17633297)
1. Antigen and vaccine banks: technical requirements and the role of the european antigen bank in emergency foot and mouth disease vaccination. Lombard M; Füssel AE Rev Sci Tech; 2007 Apr; 26(1):117-34. PubMed ID: 17633297 [TBL] [Abstract][Full Text] [Related]
2. The use of antigen and vaccine banks in case of emergency vaccination in the European community. Füssel AE Dev Biol (Basel); 2004; 119():307-15. PubMed ID: 15742642 [TBL] [Abstract][Full Text] [Related]
3. Effect of emergency FMD vaccine antigen payload on protection, sub-clinical infection and persistence following direct contact challenge of cattle. Cox SJ; Voyce C; Parida S; Reid SM; Hamblin PA; Hutchings G; Paton DJ; Barnett PV Vaccine; 2006 Apr; 24(16):3184-90. PubMed ID: 16488060 [TBL] [Abstract][Full Text] [Related]
4. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Grubman MJ Biologicals; 2005 Dec; 33(4):227-34. PubMed ID: 16289996 [TBL] [Abstract][Full Text] [Related]
5. A global virtual network for foot-and-mouth disease in case of emergency. Palma EL Dev Biol (Basel); 2004; 119():317-31. PubMed ID: 15742643 [TBL] [Abstract][Full Text] [Related]
7. Extending the foot-and-mouth disease module to the control of other diseases. De Clercq K; Goris N Dev Biol (Basel); 2004; 119():333-40. PubMed ID: 15742644 [TBL] [Abstract][Full Text] [Related]
8. [Vaccination against foot and mouth disease: current state and perspectives]. Visser N; Thiel HJ Dtsch Tierarztl Wochenschr; 2001 Dec; 108(12):522-5. PubMed ID: 11822168 [TBL] [Abstract][Full Text] [Related]
9. Regulatory considerations for emergency use of vaccines in the European Union. Pastoret PP; Mackay D Dev Biol (Basel); 2003; 114():53-8. PubMed ID: 14677676 [TBL] [Abstract][Full Text] [Related]
10. Very fast (and safe) inactivation of foot-and-mouth disease virus and enteroviruses by a combination of binary ethyleneimine and formaldehyde. Barteling SJ; Cassim NI Dev Biol (Basel); 2004; 119():449-55. PubMed ID: 15742659 [TBL] [Abstract][Full Text] [Related]
12. Application of non-structural protein antibody tests in substantiating freedom from foot-and-mouth disease virus infection after emergency vaccination of cattle. Paton DJ; de Clercq K; Greiner M; Dekker A; Brocchi E; Bergmann I; Sammin DJ; Gubbins S; Parida S Vaccine; 2006 Oct; 24(42-43):6503-12. PubMed ID: 16872727 [TBL] [Abstract][Full Text] [Related]
13. Cedivac-FMD can be used according to a marker vaccine principle. Chénard G; Selman P; Dekker A Vet Microbiol; 2008 Apr; 128(1-2):65-71. PubMed ID: 18035508 [TBL] [Abstract][Full Text] [Related]
14. [Expression of foot and mouth disease virus antigens in transgenic plants]. Dus Santos MJ; Wigdorovitz A Rev Sci Tech; 2005 Apr; 24(1):175-87. PubMed ID: 16110887 [TBL] [Abstract][Full Text] [Related]
15. Development of vaccines toward the global control and eradication of foot-and-mouth disease. Rodriguez LL; Gay CG Expert Rev Vaccines; 2011 Mar; 10(3):377-87. PubMed ID: 21434805 [TBL] [Abstract][Full Text] [Related]
16. Detection of foot-and-mouth disease virus infection in vaccinated cattle. Niedbalski W Pol J Vet Sci; 2005; 8(4):283-7. PubMed ID: 16385852 [TBL] [Abstract][Full Text] [Related]
17. European Pharmacopoeia foot-and-mouth disease vaccine potency testing in cattle: between test variability and its consequences. Goris N; Merkelbach-Peters P; Diev VI; Verloo D; Zakharov VM; Kraft HP; De Clercq K Vaccine; 2007 Apr; 25(17):3373-9. PubMed ID: 17227691 [TBL] [Abstract][Full Text] [Related]
18. The field effectiveness of routine and emergency vaccination with an inactivated vaccine against foot and mouth disease. Elnekave E; Li Y; Zamir L; Even-Tov B; Hamblin P; Gelman B; Hammond J; Klement E Vaccine; 2013 Jan; 31(6):879-85. PubMed ID: 23246551 [TBL] [Abstract][Full Text] [Related]
19. A Review of OIE Country Status Recovery Using Vaccinate-to-Live Versus Vaccinate-to-Die Foot-and-Mouth Disease Response Policies I: Benefits of Higher Potency Vaccines and Associated NSP DIVA Test Systems in Post-Outbreak Surveillance. Barnett PV; Geale DW; Clarke G; Davis J; Kasari TR Transbound Emerg Dis; 2015 Aug; 62(4):367-87. PubMed ID: 24112127 [TBL] [Abstract][Full Text] [Related]
20. Dramatic improvement in FMD DNA vaccine efficacy and cross-serotype antibody induction in pigs following a protein boost. Li Y; Stirling CM; Denyer MS; Hamblin P; Hutchings G; Takamatsu HH; Barnett PV Vaccine; 2008 May; 26(21):2647-56. PubMed ID: 18321615 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]